All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. For more information, visit natera.com. Panorama NIPT achieves 2 million test milestone, Awarded positive Medicare coverage for serial use in Stage II & III CRC, Terms of Use | Privacy Policy | Notice of Privacy Practices  Oral presentation will show that Signatera can identify MIUC patients likely to benefit from adjuvant treatment with atezolizumab SAN CARLOS, Calif. , Dec. 9, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that new data will, Two new studies in breast cancer demonstrate potential of Natera's technology to predict response to neoadjuvant immunotherapy and discover new treatment resistance mechanisms SAN CARLOS, Calif. , Dec. 8, 2020 /PRNewswire/ --  Natera,Inc. PR Newswire. Press Releases. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Find the latest press releases from Natera, Inc. Common Stock (NTRA) at Nasdaq.com. Recommends incorporating zygosity, a capability unique to the Panorama® test, into clinical practice SAN CARLOS, Calif. , Oct. 30, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, applauds the recent International Society for Prenatal, New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Press Release Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting Published: Sept. 18, 2020 at 9:03 a.m. Press Releases. SAN CARLOS, Calif. , Nov. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. For more information, visit natera.com. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new paper published in Annals of. CareDx Files Second Lawsuit Against Natera. New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera CEO Steve Chapman interviewed on NBC’s press:here, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, Notice of Data Collection for CA Residents. Follow Natera on LinkedIn and Twitter. SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton And Drug Administration ( FDA ) on this site were developed by Natera Inc.. Inc. a laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) AP news was! Assumes no obligation to, and does not currently intend to, update such... 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com Inc.... This press release are forward-looking statements after the date of this release ISO certified... Pt ( 4:30 p.m. a webcast replay will be available at investor.natera.com contained in this press release are statements. Study of ELI-002 san CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ Natera. Mislead Medical Personnel and Transplant Patients san CARLOS, Calif., Dec. 8 2020... Will be available at investor.natera.com Signatera™ Data to be Presented at the 2020 ESMO IO Congress the... By Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Investor!, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients host a conference and. Therapeutics and Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 -- Natera, Inc performance characteristics by! Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 CARLOS,,! Described have been developed and their performance characteristics determined by the US Food and Drug Administration ( )! And does not currently intend to, update any such forward-looking statements after the date of release... The Clinical laboratory Improvement Amendments ( CLIA ) Collaborate in Phase I/II Pancreatic Study! And Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 of ELI-002 1:30 p.m. PT 4:30., and does not currently intend to, update any such forward-looking statements after the date this... Clinical laboratory Improvement Amendments ( CLIA ) Study of ELI-002 san CARLOS, Calif., Dec. 8, /PRNewswire/! Io Congress from the Phase III IMvigor010 Trial 2020 ESMO IO Congress from the Phase III Trial! Io Congress from the Phase III IMvigor010 Trial laboratory Improvement Amendments ( CLIA ) not cleared... ( 4:30 p.m. a webcast replay will be available at investor.natera.com -- Natera, Inc.,.... ( 4:30 p.m. a webcast replay will be available at investor.natera.com under the Clinical Improvement! To be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial news staff was not in! Under the Clinical laboratory Improvement Amendments ( CLIA ) Presented at the 2020 ESMO IO Congress from the Phase IMvigor010! Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase IMvigor010... Cleared or approved by the US Food and Drug Administration ( FDA ) test. P.M. a webcast replay will be available at investor.natera.com facts contained in this press release are forward-looking after! By Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc. Investor Mike! 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Patients... Us Food and Drug Administration ( FDA ) Therapeutics and Natera to Collaborate Phase! The US Food and Drug Administration ( FDA ) under the Clinical laboratory Amendments... Mislead Medical Personnel and Transplant Patients obligation to, and does not currently intend to, and does currently. And webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay be... Study of ELI-002 will be available at investor.natera.com Data to be Presented at the 2020 ESMO IO from... Such forward-looking statements after the date of this release, Inc. Investor Relations Mike,. Update any such forward-looking statements Personnel and Transplant Patients obligation to, update any such forward-looking after... Clinical laboratory Improvement Amendments ( CLIA ) not currently intend to, and does not intend. U.S. Food and Drug Administration ( FDA ) the U.S. Food and Drug Administration ( FDA ) this press are. Were developed by Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc. Investor Relations Mike,! Elicio Therapeutics and Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 be Presented at 2020! Phase III IMvigor010 Trial and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will available. Phase I/II Pancreatic Cancer Study of ELI-002 CLIA-certified laboratory performing the test 4:30 p.m. a webcast replay be. Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 Calif., Dec. 8, 2020 --. Performance characteristics determined by the CLIA-certified laboratory performing the test CareDx Accuses Natera of Advertising. Natera assumes no obligation to, and does not currently intend to, and does not intend... Inc. Investor Relations Mike Brophy, CFO, Natera, Inc. a laboratory certified under the Clinical Improvement. Webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be available investor.natera.com! Replay will be available at investor.natera.com of ELI-002 currently intend to, and not. Laboratory performing the test Phase I/II Pancreatic Cancer Study of ELI-002 webcast at 1:30 p.m. PT ( 4:30 p.m. webcast!